CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 102 enrolled
Drug / intervention
Ezetimibe +8 moredrug
Likely dose
Ezetimibe 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687076
NCT00687076Phase 4Completed

Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ("The ELIMIT Trial")

Baylor College of Medicine·interventional·Posted May 30, 2008·Updated Feb 6, 2020

In Brief

A Phase 4 clinical trial evaluating Ezetimibe, Niaspan, and 7 other interventions for Peripheral Arterial Disease. Completed, enrolled 102 participants across 1 site.

Detailed Summary

Peripheral arterial disease (PAD) occurs when arteries become narrowed or hardened because of a build-up of plaque or fat deposits. PAD develops most often in arteries in the legs, which can result in reduced blood flow to the legs and feet, occasionally causing leg pain and fatigue. Early identification of PAD and treatment with lifestyle changes or medications can help to keep legs healthy and lower risk for heart attack and stroke, but endovascular or surgical procedures may be necessary for people with severe PAD. Even after endovascular intervention, PAD symptoms must be continually monitored to prevent the development and progression of blockages in the arteries. The best approach for monitoring symptoms is still undetermined. This study will compare the effectiveness of an intensive combination of lipid modifying medications versus standard lipid modifying medications in treating people with significant PAD who have had an endovascular intervention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2008
Enrollment StartApr 1, 2004
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 18.1 years ago

Interventions

Ezetimibedrug

Daily dose of 10 mg of Ezetimibe

Niaspandrug

Daily dose of 1500 mg of Niaspan

Statin therapydrug

Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)

Standard carebehavioral

Standard of medical care for PAD

Aspirindrug

Daily dose of 325 mg of aspirin

Clopidogreldrug

Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician

Placebo Niaspandrug

Daily dose of 1500 mg of placebo Niaspan

Placebo Ezetimibedrug

Daily dose of 10 mg of placebo Ezetimibe

Percutaneous transluminal angioplasty (PTA)procedure

Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.